COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00397423
Recruitment Status : Completed
First Posted : November 9, 2006
Last Update Posted : November 28, 2007
Information provided by:
Peking University

Brief Summary:

This study will examine the effectiveness of G-CSF in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and motor cortex. Patients develop progressive wasting and weakness of both upper and lower limbs, bulbar and respiratory muscles. Usually death from respiratory failure typically is within 3-5 years of diagnosis. Although there are various treatments for ALS, riluzole is the only approved treatment to delay the disease progression. G-CSF is an approved drug that is used to increase white blood cell counts. Moreover, G-CSF and its receptor are expressed by neurons. It acts anti-apoptosis by activating several protective pathways, stimulates neuronal differentiation of adult neural stem cells in the brain, and improves long-term recovery. G-CSF is a novel neurotrophic factor, and a highly attractive candidate for the treatment of neurodegenerative conditions such as ALS.

Patients 18 to 65 years of age who have had mild to moderately severe ALS for 0.5 to 2 years of duration may be eligible for this study. Candidates will be screened with a medical history and possible review of medical records, physical examination, blood test, urine and stool analyses, electrocardiogram, electrophysiological examination, neurological imaging and, for women, a pregnancy test.

Participants will have drug therapy according to randomized number. One group receives G-CSF while other group receives placebo. All of the participants receive riluzole treatment. For the procedure, patients are given a medication to lessen anxiety and any discomfort. Patients receive drug injections every 3 months for 5 days. The G-CSF dosage is 5μg/kg/day. Physical examination and interview, Appel ALS scale and ALS-Functional Rating Scale will be done in 14, 28 days and 3, 6, 9, 12 months. Electrophysiological examination will be tested per 3 months. Blood samples will be collected on treat 5, 14, 28 days and 3, 6, 9, 12 months.

Condition or disease Intervention/treatment Phase
Amyotrophic Lateral Sclerosis Drug: Granulocyte Colony Stimulating Factor Drug: NS Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Granulocyte-Colony Stimulating Factor Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response
Study Start Date : December 2006
Actual Study Completion Date : August 2007

Arm Intervention/treatment
Active Comparator: 1
Drug: Granulocyte Colony Stimulating Factor
Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd*5 days,3 months interval for 4 times

Placebo Comparator: 2
Drug: NS
NS 1ml iH Qd*5 days, 3 months interval for 4 times

Primary Outcome Measures :
  1. the mean rate of decline of ALS-FRS score [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. the mean rate decline of the AARS score [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration. The diagnosis must be supported by the Revised Criteria of the World Federation of Neurology. The grades of diagnosis must be clinically definite ALS or clinically probable ALS.
  • All subjects must be over age 18 and below 65.
  • The ALS is mildly to moderate based on ALS Health State Scale.
  • Electrophysiological features show CMAP amplitude of motor nerve normal or mild declining.
  • Serum creatine kinase is normal or mild upper, less than 500U/L.

Exclusion Criteria:

  • If anyone of the above eligibility requirements is not met
  • Use of any other investigational agent within 30 days beginning the treatment phase of this study
  • Severe cardiac, pulmonary, hepatic or/and hematic disease
  • HIV positivity or signs and symptoms consistent with HIV infection
  • Pregnant or nursing women
  • History of cancer with less than 5 years documentation of a disease-free state
  • History of anaphylactic reaction or hypersensitivity to G-CSF or proteins derived from E.coli
  • Alcohol or drug abuse in recent 1 year
  • Can't understand or obey the rules of treatment
  • Blood donor in recent 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00397423

Layout table for location information
China, Beijing
Dongsheng Fan
Beijing, Beijing, China, 100083
Sponsors and Collaborators
Peking University
Layout table for investigator information
Study Chair: Dongsheng Fan, MD Peking University Third Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00397423    
Other Study ID Numbers: R01-123456-1
First Posted: November 9, 2006    Key Record Dates
Last Update Posted: November 28, 2007
Last Verified: November 2007
Keywords provided by Peking University:
Amyotrophic Lateral Sclerosis
Granulocyte Colony Stimulating Factor
Randomized Control Trial Study
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic